Boutique Diagnostics

Digital Health Market Access Consulting Firm

Digital Health Solutions

Access

June 2022: What’s new in the world of diagnostics? – (Digital) diagnostics access / policy news around the globe

June 2022: What’s new in the world of diagnostics? – (Digital) diagnostics access / policy news around the globe

Exciting access and policy-relevant news flash around the globe from the (digital) diagnostics perspective.

Performance-based Risk-sharing Agreements in Diagnostics: Part 2, Europe

Performance-based Risk-sharing Agreements in Diagnostics: Part 2, Europe

In our second part in this mini-series, today we look at the landscape, trends and challenges in Performance-Based Risk Sharing Agreements in Europe.

Performance-based Risk-sharing Agreements in Diagnostics: Part 1 USA

Performance-based Risk-sharing Agreements in Diagnostics: Part 1 USA

We look at the first systematic review of an ever-evolving diagnostic access pathway, performance-based risk-sharing agreements, in the United States. In our next blogpost, we will review the same trends in diagnostic patient access in Europe.

Securing coverage for digital diagnostics | presentation for Zurich University of Applied Sciences

Securing coverage for digital diagnostics | presentation for Zurich University of Applied Sciences

Very recently Anastasios Gkiokas shared our view on “Securing coverage for digital diagnostic solutions”. Read the blog entry for the key highlights of his talk.

3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores)

3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores)

1. EGFR tests included for NSCLC in WHO’s third Essential Diagnostics List

2. Germany has a liquid biopsy tariff for locally advanced or metastatic NSCLC

3. Breast cancer recurrence risk scores: Oncotype DX first to be nationally reimbursed in Germany but others may soon join the game

What’s new in the WHO Essential Diagnostics List 3.0?

What’s new in the WHO Essential Diagnostics List 3.0?

The World Health Organisation recently released the third Essential Diagnostics List (EDL), which identifies the most crucial diagnostics low- and middle-income countries (LMICs) should have to fight illnesses ranging from infectious diseases to cancer.

Germany’s Digital Healthcare Act – A glimpse on the first applicants

Germany’s Digital Healthcare Act – A glimpse on the first applicants

Digital Healthcare Act (DiGAV) aims to create a solid reimbursement pathway for digital health solutions in the German healthcare market. BfArM, the body that determines which solution will be enlisted in the DiGA registry, opened its application portal in May, and it is expected to publish the first application results later this month.

Meanwhile, the umbrella association for digital healthcare acts (Spitzenverband Digitale Gesundheitsversorgung) has disclosed some of the first companies that applied for inclusion in the DiGA registry.

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

How does the UK's NICE evaluate diagnostic technologies? 1-pager summary

Download Insights – Prostate Cancer Diagnostics Solutions

Download Insights – Prostate Cancer Diagnostics Solutions

Prostate cancer is the 2nd most commonly diagnosed cancer amongst men. Many men also go through invasive biopsies that yield negative results.

What tests are used to diagnose prostate cancer, minimize invasive biopsies, and improve prognosis? Check out our short report.

Did you miss ISPOR Europe 2019? Check out these 5 insightful diagnostics posters

Did you miss ISPOR Europe 2019? Check out these 5 insightful diagnostics posters

ISPOR took place on 4-6 November 2019, in Copenhagen, Denmark. Check out these 5 diagnostics posters from over 2,600 poster presentations.